Background {#Sec1}
==========

Multidrug use, often termed "polypharmacy," has negative consequences \[[@CR1], [@CR2]\]. However, there is a lack of evidence that multidrug use triggers adverse events. Some reports suggested a relationship between the number of drugs and lower rate of adherence \[[@CR3]\], risk of potential drug-drug interactions \[[@CR4]\], and inappropriate prescriptions, such as potentially inappropriate medications (PIMs).

PIMs pose a high risk of adverse events in the elderly and should be avoided. Two sets of criteria for PIMs, the Beers criteria \[[@CR5]\] and the Screening Tool of Older Persons' Prescriptions (STOPP) \[[@CR6], [@CR7]\], are used globally. In Japan, the "Screening Tool for Older Persons' Appropriate Prescriptions for Japanese (STOPP-J) \[[@CR8]\]" is used. The use of drugs related to the Beers or STOPP criteria and the consequent under-prescribing of medications were reported to be frequent in patients receiving multidrug treatment \[[@CR9]--[@CR11]\]; similar reports were also published in Japan \[[@CR12], [@CR13]\]. We hypothesize that adverse events tend to occur in patients receiving multidrug treatment because of high-risk prescriptions. However, to date, a detailed analysis from this perspective has not been performed.

This study aimed to clarify the relationship between total number of drugs and high-risk prescriptions administered to Japanese elderly patients, and to clarify whether hospitalization rate and concomitant medication differ based on high-risk prescriptions used by these patients.

Methods {#Sec2}
=======

Survey method and subjects {#Sec3}
--------------------------

This survey was conducted at Chiba University Hospital, which has 37 clinical departments conducting consultations for an estimated 2500 outpatients/day. Using the electronic medical records (EMR) system at this hospital, we surveyed prescriptions for outpatients aged ≥65 years who were presented at this hospital between October--December 2016 and prescribed at least one regular medication. All regular medications except for as-needed medications, injections, and topical drugs were analyzed.

Examination of prescriptions and hospitalization {#Sec4}
------------------------------------------------

We extracted 21 categories from the list of drugs that should be prescribed with special caution in the STOPP-J; these were defined as PIMs. In the STOPP-J, eight categories had limited disease and patient background, which were excluded from PIMs because it was impossible to extract their data from the EMR using our method.

To find overlapping of drugs with the same mechanism of action (DSAs), we surveyed drugs with anticholinergic effects (39 drugs) and benzodiazepine receptor agonists (22 drugs). DSAs include drugs with different medical effects. Because constipation is a typical adverse event of anticholinergic action, we considered that laxative prescription may be an indicator for the occurrence of adverse events.

We defined prescriptions of PIMs and overlapping prescription of DSAs as high-risk prescriptions. We examined the relationship between the number of drugs and high-risk prescriptions. We also investigated the number of hospitalizations that occurred for one year following the prescription survey (January to December 2017).

Statistical analysis {#Sec5}
--------------------

To compare the median values of PIMs, the Mann-Whitney U test was performed following the Kruskal-Wallis test. Correlation between the total number of prescribed drugs and number of PIMs was obtained using the Spearman's rank correlation coefficient. For the prescription status of PIMs and overlapping DSAs, we performed a χ^2^ test or Fisher's exact test, as appropriate. Logistic regression analysis was performed on the prescription of PIMs and the effect of the number of PIMs on hospital admission. All analyses were carried out using IBM SPSS Statics ver. 23 (IBM Corp., Armonk, NY). Significance was set to 5%, and correction for multiple comparisons was conducted using the Bonferroni method.

Results {#Sec6}
=======

Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. A total of 11,241 elderly outpatients received at least one regular medication. As the total number of drugs increased, the prescription frequency of PIMs also increased (Table [2](#Tab2){ref-type="table"}). For 17 of the 21 PIM categories, prescription frequency was significantly higher in the 5--9-drugs group than in the 1--4-drugs group. It was similar in the 10 or more-drugs group, compared to the 1--4-drugs group. A significant correlation was found between the number of PIMs and total number of prescribed drugs ((Fig. [1](#Fig1){ref-type="fig"}, Spearman's *r* = 0.529, *p* \< .001). The median number of PIMs was 0, 1, and 2 in the 1--4-, 5--9-, and 10 or more-drugs groups (*p* \< .001 in each case), respectively.Table 1Patient CharacteristicsCharacteristicsAll categories1--4 drugs5--9 drugs≥10 drugs*n* = 11,241*n* = 7723*n* = 2802*n* = 716(% or range)(% or range)(% or range)(% or range)Sex Male5653 (50.3)3765 (48.8)1430 (51.0)393 (54.9) Female5588 (49.7)3958 (51.2)1372 (49.0)323 (45.1)Median age (years)73 (65--100)73 (65--98)73 (65--95)73 (65--100)Age group 65--74 years6444 (57.3)4384 (56.8)1646 (58.7)414 (57.8)  ≥ 75 years4797 (42.7)3339 (43.2)1156 (41.3)302 (42.2)Median number of prescribed drugs3 (1--25)2 (1--4)6 (5--9)11 (10--25)Median number of consultation departments^†^1 (1--6)1 (1--3)1 (1--5)2 (1--6)†The Mann-Whitney U test was used after the Kruskal-Wallis test to compare the differences among groups. Correction by the Bonferroni method was performed, and *p* \< .017 was considered statistically significant. In the comparison of medians between the 1--4-drugs and 5--9-drugs groups, the 1--4-drugs and 10 or more-drugs groups, and the 5--9-drugs and 10 or more-drugs groups, each *p* value was \< .001Table 2Prevalence of drugs that should be prescribed with special cautionPIMs\
(Drug class or generic names)All categories\
*n* = 11,2411--4 drugs\
*n* = 7723 (%)5--9 drugs\
*n* = 2802\
(%)≥ 10 drugs\
*n* = 716\
(%)*p* values1--4 vs1--4 vs5--9 vs5--9 drugs≥10 drugs≥10 drugsBenzodiazepine derivatives770280 (3.6)330 (11.8)160 (22.3)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^Non-benzodiazepine hypnotics380149 (1.9)166 (5.9)65 (9.1)\< .001^†\*\*^\< .001^†\*\*^.002^†\*\*^Tricyclic antidepressants4520 (0.3)15 (0.5)10 (1.4).035^‡^\< .001^‡\*\*^.022^‡^Sulpiride247 (0.1)10 (0.4)7 (1.0).005^‡\*^\< .001^‡\*\*^.061^‡^Antiparkinsonian drugs (anticholinergic drugs)3516 (0.2)18 (0.6)1 (0.1).001^‡\*^NA.150^‡^Combined therapy with multiple27042 (0.5)123 (4.4)105 (14.7)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^antithrombotic drugs(antiplatelet drugs, anticoagulants)Digoxin (\>  0.125 mg/day)60 (0.0)3 (0.1)3 (0.4).019^‡^\< .001^‡\*\*^.103^‡^Loop diuretics59684 (1.1)299 (10.7)213 (29.7)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^Aldosterone antagonists40993 (1.2)186 (6.6)130 (18.2)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^α1-Receptor blockers10527 (0.3)40 (1.4)38 (5.3)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^(nonselective for receptor subtypes)H~1~ receptor antagonists4920 (0.3)19 (0.7)10 (1.4).003^‡\*^\< .001^‡\*\*^.065^‡^(first generation)H~2~ receptor antagonists647234 (3.0)301 (10.7)112 (15.6)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^Antiemetic drugs12635 (0.5)68 (2.4)23 (3.2)\< .001^‡\*\*^\< .001^‡\*\*^\< .001^‡\*\*^Sulfonylureas17326 (0.3)107 (3.8)40 (5.6)\< .001^†\*\*^\< .001^†\*\*^.035^†^Biguanides29168 (0.9)163 (5.8)60 (8.4)\< .001^†\*\*^\< .001^†\*\*^.012^†\*^Thiazolidine derivatives8924 (0.3)45 (1.6)20 (2.8)\< .001^‡\*\*^\< .001^‡\*\*^.043^‡^α-Glucosidase inhibitors21246 (0.6)101 (3.6)65 (9.1)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^SGLT2 inhibitors409 (0.1)25 (0.9)6 (0.8)\< .001^‡\*\*^.001^‡\*\*^NAOxybutynin (oral)32 (0.0)1 (0.0)0 (0.0)NANANAMuscarinic receptor antagonists13971 (0.9)39 (1.4)29 (4.1).035^†^\< .001^†\*\*^\< .001^†\*\*^NSAIDs836344 (4.5)341 (12.2)151 (21.1)\< .001^†\*\*^\< .001^†\*\*^\< .001^†\*\*^The target PIMs are "drugs to be prescribed with special caution" to the elderly according to the Medications for the Elderly Guidelines 2015, or drugs that can be extracted from the electronic medical records (EMR) even if the target population is limited. Sliding-scale insulin was excluded because it could not be extracted from the EMR. ^†^ The *χ*^2^ test or ^‡^Fisher's exact test was used to compare the differences between each group. Correction with the Bonferroni method was performed, and *p* \< .017 (*p* \< .025 for antiparkinsonian drugs and SGLT2 inhibitors) was considered significant. \**p* \< .017 (*p* \< .025); \*\**p* \< .003 (*p* \< .005). NA, not applicableFig. 1Relationship between the total number of drugs and the number of PIMs. Prescription ratio of PIMs by total number of drugs

Percentage of overlapping prescription of anticholinergics or benzodiazepine receptor agonists in the 5--9-drugs group was higher than in the 1--4-drugs group (Fig. [2](#Fig2){ref-type="fig"}). No significant difference in overlapping prescription for anticholinergics or benzodiazepine receptor agonists was found between the 5--9-drugs and 10 or more-drugs groups. Patients receiving overlapping prescriptions for anticholinergic drugs received significantly more prescriptions for laxatives \[OR 2.44 (95% CI, 1.30--4.61)\].Fig. 2Overlapping drugs with the same mechanism of action. (a) Overlapping anticholinergic drugs (b) Overlapping benzodiazepine receptor agonists The *χ*^*2*^ test was used to compare the differences between each group (a,b). Correction with the Bonferroni method was performed, and *p* values \< .017 were considered significant. \**p* \< .017

In the year following the prescription survey, 1900 (16.9%) patients in the study were hospitalized (Table [3](#Tab3){ref-type="table"}). We identified loop diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs) as independent risk factors for hospitalization \[OR 1.73 (95% CI, 1.38--2.16) and 1.29 (95% CI, 1.08--1.54), respectively\]. The number of PIMs was an independent risk for hospitalization \[OR 1.18 (95% CI, 1.12--1.26), *p* \< .001\], but not the use of PIMs other than loop diuretics and NSAIDs.Table 3Results of multiple logistic- regression analysis of PIMs-related risk factors that can affect hospitalizationNumber of patientsAdjusted^†^ OR (95% CI)*p* valuehospitalized/Total (%)Age0.99 (0.98--0.99).001^\*\*^Sex Male1113/5653 (19.7)1.56 (1.40--1.72)\< .001^\*\*\*^ Female787/5588 (14.1)Total number of drugs1.06 (1.03--1.08)\< .001^\*\*\*^Number of medical departments1.43 (1.29--1.59)\< .001^\*\*\*^Benzodiazepine derivatives142/770 (18.4)0.90 (0.74--1.10)0.314Non-benzodiazepine hypnotics78/380 (20.5)1.11 (0.85--1.45)0.439Tricyclic antidepressants9/45 (20.0)1.09 (0.51--2.35)0.821Sulpiride2/24 (8.3)0.36 (0.81--1.58)0.173Antiparkinsonian drugs4/35 (11.4)0.64 (0.22--1.84)0.409(anticholinergic drugs)Combined therapy with multiple antithrombotic drugs80/270 (29.7)1.26 (0.94--1.69)0.116(antiplatelet drugs, anticoagulants)Digoxin (\>  0.125 mg/day)1/6 (16.7)0.27 (0.30--2.48)0.249Loop diuretics198/596 (33.2)1.73 (1.38--2.16)\< .001^\*\*\*^Alderostone antagonists123/409 (30.1)1.24 (0.95--1.61)0.108α1-Receptor blockers20/105 (19.0)0.74 (0.44--1.24)0.25nonselective for receptor subtypesH~1~ receptor antagonists11/49 (22.4)0.98 (0.49--1.98)0.965(first generation)H~2~ receptor antagonists107/647 (16.5)0.80 (0.64--0.99).044^\*^Antiemetic drugs34/126 (27.0)1.45 (0.96--2.19)0.079Sulfonylureas27/173 (15.6)0.71 (0.45--1.12)0.14Biguanides49/291 (16.8)0.82 (0.58--1.17)0.274Thiazolidine derivatives10/89 (11.2)0.53 (0.27--1.08)0.079α-Glucosidase inhibitors45/212 (21.2)1.04 (0.72--1.50)0.847SGLT2 inhibitors4/40 (10.0)0.48 (0.17--1.42)0.185Muscarinic receptor antagonists18/139 (12.9)0.58 (0.35--0.96)0.036Oxybutynin (oral)0/3 (0)NANSAIDs197/836 (23.5)1.29 (1.08--1.54).006^\*\*†^Adjusted for age, sex, number of medical departments, and use of other PIMs. The odds ratio (OR) was calculated using logistic regression analysis. *p* \< .05 was considered statistically significant. ^\*^*p* \< .05; ^\*\*^*p* \< .01; ^\*\*\*^*p* \< .001. NA, not applicable

Discussion {#Sec7}
==========

This study showed that increases in the total number of drugs prescribed for outpatients were associated with the prescribing of more PIMs and more overlapping DSA. Previous reports on prescriptions for the elderly in Japan are limited. As this survey obtained similar results to those of other countries, increased PIMs due to multidrug use may be a common issue across countries. Presently, little information exists on the status of the prescription issuance of PIMs in the STOPP-J. Therefore, our findings may be useful for future medical care of the elderly in Japan.

Our findings showed that overlapping DSAs increased remarkably in the 5--9-drugs group compared to that in the 1--4-drugs group. We found many cases where laxatives were prescribed for patients receiving overlapping drugs with anticholinergic effects, suggesting that drug-induced constipation increased owing to the overlapping of drugs with anticholinergic effects. The proportion of overlapping DSAs was markedly higher in the 5--9-drugs group than in the 1--4-drugs group without significant difference. Kojima et al. reported that falling and other drug-related adverse events increase in elderly patients concurrently using more than 5 or 6 drugs \[[@CR14], [@CR15]\], and our results may explain one of these events.

We also found that the number of PIMs was an independent risk factor for hospitalization, but the use of PIMs except for loop diuretics and NSAIDs was not. The presence or absence of PIMs was reported to affect hospitalization \[[@CR16], [@CR17]\], and a high number of hospitalizations was indicated in patients using specific drugs, such as loop diuretics and NSAIDs \[[@CR18], [@CR19]\]. It was reported that the use of loop diuretics is more likely to lead to cardiac death and re-hospitalization, even after correction for differences in background factors, including the severity of heart failure \[[@CR20]\]. Reports showed that the use of NSAIDs is the most common cause of drug adverse events in elderly people, and that the use of NSAIDs has increased \[[@CR21]\]. We think that these reports support our results. However, all hospitalizations in our study were not the results of drug adverse events; thus, future studies are warranted.

To date, there are several reports that multidrug use is associated with adverse events and hospitalization \[[@CR2], [@CR14], [@CR15], [@CR22]\]. However, the mechanisms by which multidrug use increases these risks remain unknown. In addition, as mentioned above, PIMs affect adverse events and hospitalization. Our results clearly showed that multidrug use was correlated with increased high-risk prescriptions, i.e., the number of PIMs and overlapping DSAs. This result may be linked to increased risk of adverse events and hospitalization due to multidrug use. It was also reported that reviewing a patient's prescription reduces the risk of re-hospitalization of the patient \[[@CR23]\]. Therefore, reviewing high-risk prescriptions might prevent adverse events and hospitalization.

Our study had several limitations. First, our study analyzed only the drugs prescribed in our hospital. Therefore, it is possible that the results of this survey underestimated the actual state of prescription issuance. The total number of prescribed drugs was lower than that reported in other studies in Japan \[[@CR12], [@CR24]\]. Second, we did not examine any prescription changes during the study period. Third, we were unable to include hospitalization that occurred in other hospitals. In addition, our method could not be used to analyze, in-depth, the backgrounds of the hospitalized patients. There are several reports showing the relationship between multidrug use and frailty, decreased activities of daily living, decreased renal function, and worsening of nutritional status \[[@CR24]\]. More knowledge can be obtained by identifying these conditions and conducting detailed analysis.

Multidrug use is often considered inappropriate under any circumstances. A more nuanced view holds that a combination of more drugs than necessary should be defined as "polypharmacy," for distinction from appropriate multidrug combinations \[[@CR25]\]. Our results may contribute to elucidate multidrug combinations that should be avoided.

Conclusion {#Sec8}
==========

This study revealed that the number of PIMs and overlapping DSAs were higher in patients receiving multidrug treatment, and that the number of PIMs was an independent risk factor for hospitalization. Reviewing prescriptions and considering the number of PIMs and overlapping DSAs may reduce adverse events and hospitalization.
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